New Delhi, July 23 -- India's pharmaceutical market is entering the proposed two-year transition period before the United States' planned tariffs on imported generic medicines with broad-based domestic growth momentum, according to an Equirus Securities report, which highlighted strong demand across therapies and leading drugmakers.

US President Donald Trump on Wednesday announced that all generic drugs imported into the United States will continue to attract zero per cent tariffs for two years from August 1, 2026, after which tariffs will rise by up to 200 per cent over two consecutive years.

Against this backdrop, the report said the Indian Pharmaceutical Market (IPM) posted its strongest monthly performance in more than two years in ...